Grifols holds its Annual General Meeting with 76.7% of the company’s share capital represented

Grifols sets payout at 40% of consolidated net profit

- Shareholders endorse management team and ratify all the points on the agenda
- Shareholders approve the allocation of 137.5 million euros to dividends, distributed in two payments: an interim dividend of 0.20 euros (gross) per share, paid in June 2013, and a second dividend for the same amount to be paid on June 5, 2014
- Interim dividend on account of 2014 results foreseen before year end announced
- Number of directors increased to 13, with the appointment of Ms. Marla E. Salmon as a new, independent, external director

Barcelona, May 30, 2014: Grifols (MCE:GRF,MCE:GRF.P and NASDAQ:GRFS), one of the world’s leading companies in the plasma-derived biological medicines and transfusion medicine sectors, has held its Ordinary General Meeting of Shareholders on second call. 605 shareholders were represented; accounting for 163,557,616 Class A shares, representing 76.7% of the company’s voting share capital.

The votes delegated to the Board of Directors represented approximately 56.51% of the company’s share capital, demonstrating shareholders’ confidence in the management and the group’s business plan. A key event during 2013 was the acquisition of the diagnostic transfusion unit of Novartis. The transaction was completed on January 9, 2014, leading to the expansion of Grifols’ Diagnostic division and creating a vertically integrated company capable of offering solutions to blood donor centers on the basis of a comprehensive portfolio of immunohematology products.

Internationalization continues to be one of the strategic drivers of the company. As part of this process and to underpin the group’s organic growth, Grifols will allocate 600 million euros to capital expenditure during the period 2014–2016, with the aim of ensuring manufacturing capacities and technical and human resources required to achieve this goal.

Debt reduction remains a priority for Grifols. The success of the refinancing process, completed in the first quarter of 2014, has delivered a two-point reduction in average debt costs, which now stand at below 3.5%. To achieve this strategy of rapid deleveraging, the group counts with high and sustainable levels of operating activity and cash generation.
Key points on the agenda endorsed by shareholders include:

- Approval of the annual accounts, both individual and consolidated, consisting of the balance sheet, profit and loss account, statement of changes in net equity, cash flow statement, and the corresponding management reports.
- Reappointment of the auditors.
- The appointment of Ms. Marla E. Salmon as new independent director of Grifols for a statutory term of 5 years, thus increasing the number of directors of the company’s Board to 13.
- Remuneration for external directors that do not provide any paid professional service to the company during the year, of 100,000 euros (gross) in 2014.

Shareholders also agreed by a majority to renew the delegation of powers to the Board of Directors for a possible stock split of class A and class B shares on the same terms as those proposed in December 2012, and to apply for the listing of class A shares on the NASDAQ.

**Grifols will distribute 40% of the group’s consolidated net profit to its shareholders**

The Board of Directors of Grifols has agreed to pay a final dividend of 0.20 euros (gross) for each Class A and Class B share, charged to the 2013 results. This involves allocating to dividends a total of 137.5 million euros in the financial year, following the distribution of an interim payment for the same amount on June 5, 2013. As a result, the company’s payout will be 40% of the group’s consolidated net profit.

This new dividend will be paid on June 5, 2014 through Iberclear, with BBVA as appointed payment agency.

In addition, the Board of Directors announced a new interim dividend on account of 2014 results foreseen before the end of the year.

Grifols has kept its commitment to maintain the maximum level of reward for its shareholders, who demonstrated their confidence in the company’s management and its future in 2011 and 2012 by approving the allocation of all profits achieved on those years to voluntary reserves, receiving class B, fully paid up shares as payment.

**About Grifols**

Grifols is a global healthcare company with a 70-year legacy of improving people’s health and well being through the development of life-saving plasma medicines, diagnostics systems, and hospital pharmacy products.

The company is present in more than 100 countries worldwide and is headquartered in Barcelona, Spain. Grifols is a leader in plasma collection with a network of 150 plasma donor centers in the U.S., and a leading producer of plasma-derived biological medicines. The company also provides a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks and transfusion centers, and is a recognized leader in transfusion medicine.
In 2013, sales exceeded 2,740 million euros with a headcount of 13,200 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com.

Legal Disclaimer

The facts and figures contained in this report which do not refer to historical data are “projections and forward-looking statements”. The words and expressions like “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “try to achieve”, “estimate”, “future” and similar expressions, insofar as they are related to Grifols Group, are used to identify projections and forward-looking statements. These expressions reflect the assumptions, hypothesis, expectations and anticipations of the management team at the date of preparation of this report, which are subject to a number of factors that could make the real results differ considerably. The future results of Grifols Group could be affected by events related to its own activity, such as shortages of raw materials for the manufacture of its products, the launch of competitive products or changes in the regulations of markets in which it operates, among others. At the date of preparation of this report Grifols Group has adopted the measures it considers necessary to offset the possible effects of these events.

Grifols, S.A. does not assume any obligation to publicly inform, review or update any projections and forward-looking statements to adapt them to facts or circumstances following the preparation of this report, except as specifically required by law. This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market Law 24/1988, of July 28, the Royal Decree-Law 5/2005, of March 11, and/or Royal Decree 1310/2005, of November 4, and its implementing regulations.